Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Total Liabilities: 2010-2025

Historic Total Liabilities for Heron Therapeutics (HRTX) over the last 13 years, with Sep 2025 value amounting to $234.1 million.

  • Heron Therapeutics' Total Liabilities fell 10.24% to $234.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $234.1 million, marking a year-over-year decrease of 10.24%. This contributed to the annual value of $266.8 million for FY2024, which is 4.02% up from last year.
  • As of Q3 2025, Heron Therapeutics' Total Liabilities stood at $234.1 million, which was down 9.75% from $259.3 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Total Liabilities registered a high of $266.8 million during Q4 2024, and its lowest value of $114.7 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $256.5 million (2023), whereas its average is $252.7 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first spiked by 124.67% in 2021, then dropped by 10.24% in 2025.
  • Heron Therapeutics' Total Liabilities (Quarterly) stood at $228.1 million in 2021, then grew by 4.05% to $237.4 million in 2022, then climbed by 8.05% to $256.5 million in 2023, then increased by 4.02% to $266.8 million in 2024, then decreased by 10.24% to $234.1 million in 2025.
  • Its last three reported values are $234.1 million in Q3 2025, $259.3 million for Q2 2025, and $264.2 million during Q1 2025.